|
Isis
ISIS Pharmaceuticals just signed a deal which is expected to skyrocket.
Genzyme and Isis inked a deal where Genzyme would buy $5M shares at $30 a share, and Genzyme will pay Isis $350M in licensing fees. Isis will also receive up to $750M in commercial milestone payments and $825M in development.
As per the deal, the profit will split 70/30 for Genzyme/Isis until the $2B mark is met and then each company will get 50% of the profits.
The drug is called Mipomersen and it is a cholesterol reduction drug.
This is expected to
|